We are proud to announce that we’re expanding our #DNAsynthesis capabilities to support needs across yield, complexity, and scale—from rapid production of high-diversity designs in early development, to dependable manufacturing for larger, longer-term programs. Read more: https://idtb.io/3yk3haww

The future of gene editing depends on understanding what happens beyond the target site. Learn how UNCOVERseq™ is helping advance precision #geneediting and support #translationalresearch and #therapeuticdevelopment in our latest blog: https://idtb.io/8wqtl7yy

IDT is defining the standard for safer #genomeediting.🧬 We’re delighted to share a peer-reviewed Nature Communications study—establishing that IDT’s UNCOVERseq™ delivered the strongest combined sensitivity and precision among evaluated CRISPR off-target nomination methods: https://idtb.io/dn5gelwl

We’ve got an exciting line up of posters at #CSHL2026! This is your chance to learn more about our #CRISPR portfolio from IDT scientists. Take a look below to see what’s up for discussion—see you there: https://meetings.cshl.edu/meetings.aspx?meet=crispr #CSHL #genetherapy #genomeediting

There’s still time to register for our next webinar! Join us to discover how targeted sequencing workflows are helping researchers generate high-quality #genomicdata, strengthen outbreak investigations, and better understand pathogen transmission: https://ow.ly/ov5P50Zv4TM

We are thrilled to host a workshop at #CSHL2026! Learn more about IDT’s CRISPR toolbox, how we support all workflows from early discovery to translational research, and how our solutions can accelerate genome editing programs from discovery to IND-enabling studies: https://go.idtdna.com/cshl2026

Our upcoming webinar with GenomeWeb will explore targeted sequencing strategies with insights into assay design workflow efficiency, and data comparability across platforms. Register here: https://event.on24.com/wcc/r/5400914/DCB0D959A28CD258F85861EDC040D2D9?partnerref=eblast1

Boost your edits, fast-track your breakthrough✨ Our Alt-R™ HDR Enhancer Protein improves HDR efficiency across established and primary cell types. Matthew Porteus, CSO of Kamau Therapeutics, talks about his experience with the enhancer protein below—check it out! https://ow.ly/6twB50ZupLK

IDT & Ansa Biotechnologies are here to help you push boundaries with longer DNA constructs, challenging motifs, and higher complexity backed by a partner trusted for consistency & accuracy. Together, we empower researchers to confidently tackle their most complex projects: https://ow.ly/s5TN50ZqTaB

𝗛𝗲𝗹𝗽𝗶𝗻𝗴 𝘀𝘆𝗻𝘁𝗵𝗲𝘀𝗶𝘀 𝗸𝗲𝗲𝗽 𝗽𝗮𝗰𝗲 𝘄𝗶𝘁𝗵 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆: Take a peek inside the partnership with @idtdna.bsky.social in this article by Christopher Vakulskas, who truly put us through our paces. bit.ly/3R1cECC

Helping synthesis keep pace with discovery: Inside the IDT-Ansa partnership

The pace of synthetic biology is accelerating—and with it, the complexity of the DNA constructs researchers are being asked to design, build, and validate. Longer constructs, difficult motifs, and inc...

bit.ly

Multiplex qPCR has become a go-to approach for researchers looking to maximize sample value while improving throughput and reducing costs. However, unlocking its full potential requires thoughtful assay design, optimization, and validation. Ashlee Strubberg shares insights: https://ow.ly/Fvso50ZolCt

IDT's Steven Henck and Scott McCuine explain that making #MCED and #MRD a reality requires overcoming hurdles in sample quality, assay sensitivity, workflow complexity, and regulatory and market readiness to enable broad adoption: https://www.nature.com/articles/d42473-026-00051-2

IDT's Rolf Turk shares perspectives on how continuous improvement, strategic collaboration, and innovation can help accelerate scientific discovery and advance the future of life sciences: https://ow.ly/20uY50Zn0jC

Driving Innovation Through Continuous Improvement in Life Sciences

Driving Innovation Through Continuous Improvement in Life Sciences By Rolf Turk, Senior Director - Innovation Programs, Integrated DNA Technologies - The beauty of science lies in an unrelentless quest towards discovery, innovation and application.

ow.ly

As CRISPR-based research and therapies continue to advance, understanding and minimizing off-target effects is critical for ensuring reliable, reproducible, and safe genome editing outcomes. Read more: https://idtb.io/tsi4wm5a

IDT’s trusted expertise 🤝 Ansa’s enzymatic DNA synthesis platform Push boundaries with DNA constructs up to 50kb, challenging motifs, and higher complexity backed by a partner trusted for consistency and accuracy. We empower researchers to tackle their most complex projects: http://idtb.io/07t7jr

New, free app note!📣 We collaborated with Mission Bio to highlight how Nechama Kalter & the Ayal Hendel lab are characterizing CRISPR edits in primary T cells. 🔗Download it here: https://ow.ly/h6mj50Z8QEI

The revolutionary potential of CRISPR-Cas gene editing is undeniable, but moving from the bench to the bedside requires navigating a complex landscape of off-target assessments. 🔗 Read more in our latest blog: idtb.io/m2cuocne

As #clinicalNGS continues its expansion, labs face pressure to balance innovation with compliance. IDT's Ashleigh Dawley explores how labs can build scalable, audit-ready workflows—from validating #bioinformatics platforms to selecting the right reagents and partners: https://ow.ly/qaQE50Z9mVj

Boost your edits and fast-track your breakthrough. 🚀 Learn how our Alt-R™ HDR Enhancer Protein improves CRISPR knock-in efficiency by promoting HDR pathway precision—seamlessly integrated into workflows. Discover what’s possible here: https://idtb.io/qvbm5v

IDT LOVES SUPPORTING iGEM! We offer up to 40kb of gBlocks™ Gene Fragments or equivalent value of IDT products—but only to registered teams! Make sure you register with us by September 21. Learn more here: https://idtb.io/79d14nf3

#ESHG is in full swing, and we’re having a blast! 🙌 Remember to stop by booth #622—our trusted experts are ready to discuss how our #NGSsolutions can support your research, from amplification to hybrid capture and automation-friendly library prep. See you soon! 👋

MCED and MRD research are redefining what’s possible in #cancerresearch. The challenge? Identifying one fragment of tumor DNA among millions—and doing it with consistency, at scale, in research workflows. Read more from Steven Henck and Scott McCuine: https://ow.ly/znM750ZauXH

As #clinicalNGS continues its expansion, labs face pressure to balance innovation with compliance. IDT's Ashleigh Dawley explores how labs can build scalable, audit-ready workflows—from validating #bioinformatics platforms to selecting the right reagents and partners: https://ow.ly/qaQE50Z9mVj

New, free app note!📣 We collaborated with Mission Bio to highlight how Nechama Kalter & the Ayal Hendel lab are characterizing CRISPR edits in primary T cells. 🔗Download it here: https://ow.ly/h6mj50Z8QEI

We’re a week away from #ESHG2026! 🙌 Join IDT experts at booth #622 to explore how our #NGS solutions can support reproducible, scalable, and automation‑ready workflows across your research. Discover how we can help your lab to move from discovery to insight: https://2026.eshg.org/

As #CRISPR programs move closer to the clinic, confidence in gene editing safety becomes just as critical as editing efficiency. Our CRISPR Off-target Analysis Services are designed to help you identify and prioritize off-target edits early—so you can advance with clarity: https://idtb.io/cgov2wdq

We’re proud to unveil our latest partnership with Illumina! 🤝 This collaboration will enable an integrated, end-to-end solution for somatic #oncologyresearch by combining Illumina’s DRAGEN™ secondary analysis with IDT’s xGen™ FFPE and cfDNA workflows. Read more: https://idtb.io/vpoxzw27

In recognition of National Cancer Research Month, we’re highlighting how MRD assessment and MCED are transforming #cancercare strategies. Learn more about how IDT’s advanced #NGS solutions are powering the research behind this progress: https://idtb.io/xtkf2o #cancerresearch #oncologyresearch

ICYMI: The potential of CRISPR-Cas gene editing is undeniable, but moving from the design to delivery requires navigating off-target assessments. 🔗 Read more in our latest blog: https://idtb.io/qnfzlpic #offtargetassessment #CRISPRgeneediting

We’re partnering with Ansa to provide customers with access to long, #complexDNA, ranging from 100 bp to 50 kb! Take a look at how this collaboration has delivered value to Manos Papadakis, senior research scientist, dsm-firmenich. 👇 Learn more here: www.idtdna.com/complexDNA